I-Mab (IMAB) has entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech Co., Ltd., gaining rights to bispecific and multi-specific applications based on the Claudin 18.2 parental antibody used in its CLDN18.2 x 4-1BB bispecific antibody, givastomig.
Under the agreement, I-Mab will pay Bridge Health shareholders an upfront $1.8 million plus non-contingent payments totaling $1.2 million through 2027. The transaction is expected to close in the third quarter of 2025.
Sean Fu, PhD, MBA, Chief Executive Officer of I-Mab, stated that this deal strengthens upstream intellectual property rights, reduces future milestone payments, and frees givastomig from future royalties.